THERAKOS® CELLEX® Photopheresis System

THERAKOS® CELLEX® Photopheresis System

Therakos Cellex delivers a fully integrated, automated extracorporeal photopheresis (ECP) system, providing superior efficiency, safety, and patient outcomes.

Key advantages:

  1. Faster treatment times*1:
    • Single-needle mode: 105 mins/Treatment
    • Double-needle mode: 75 mins/Treatment
  2. Only Online, integrated device to be approved by both FDA and EU certified.
  3. Workday Limitation: Based on a 7.5-hour workday (450 minutes)*2, integrated systems triple patient throughput, maximizing efficiency and bed utilization in clinical settings.
  4. compact and integrated system that enhances mobility.
  5. Single machine performs cell collection, ECP treatment and reinfusion of treated blood back to the patient, thus reducing the hidden cost.

1. Data on file. Ref-01420. Mallinckrodt Pharmaceuticals

2. Azar N, Leblond V, Ouzegdouh M, Button P. A transition from using multi-step procedures to a fully integrated system for performing extracorporeal photopheresis: A comparison of costs and efficiencies. J Clin Apher. 6 2017 Dec;32(6):474-478. doi: 10.1002/jca.21542. Epub 2017 Apr 17. PMID: 28419561; PMCID: PMC5724655

How the THERAKOS CELLEX System Works:
  • Blood Collection: The patient’s blood is drawn, and the white blood cells (including T cells) are separated from the rest of the blood using centrifugation.
  • Photoactivation:
    • A photosensitizing agent, such as 8-methoxypsoralen (8-MOP), is introduced. This agent makes T cells sensitive to ultraviolet A (UVA) light.
    • The separated white blood cells are then exposed to UVA light, which damages the DNA of the treated cells, rendering them apoptotic (programmed cell death).

  • Reinfusion: The treated white blood cells are reinfused back into the patient, where they induce an immunomodulatory effect by stimulating regulatory T cells (Tregs) and reducing inflammation or abnormal immune responses.

Value Proposition

Cellex – a completely connected, inline device which requires only 90 minutes for a whole treatment as against the 240 to 270 minutes required by other machines…

100 Reduced Hospital Stays
500 Improved Transplant Outcomes
4200 Smiling Customer

Our THERAKOS® CELLEX® Customers

Our customers are the pillars of our strength and motivation to strive for a better tomorrow.

Global Partnerships

Latest Blogs

Our latest published articles

Interested to know more?

The THERAKOS® CELLEX® provides clinicians with the ability to implement hypothermic oxygenated perfusion (HOPE) protocols with an easy-to-use and simple-to-setup system requiring minimal personnel to monitor perfusion progress.

Request a Demo